FindTrial
Sign In

Immunotherapy in Childhood with Hodgkin Lymphoma- Real World Data

Immunotherapy in Children and Adolescents with Hodgkin Lymphoma Real World Data - NIL

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/11/076407
Enrollment
50
Registered
2024-11-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C768- Malignant neoplasm of other specified ill-defined sites

Interventions

Intervention1: NIL: NA

Sponsors

CanKids KidsCan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Children aged between 0-21 years who has received agents Brentuximab, Nivolumomab, Pembroluzimab from January 2018- December 2023 2. Full Records and follow-up should be available

Exclusion criteria

Exclusion criteria: 1. Full records unavailable. 2. Follow-up details unavailable

Design outcomes

Primary

MeasureTime frame
response of various immunotherapeutic agents in children and adolescents with HL in IndiaTimepoint: 2 Years—

Secondary

MeasureTime frame
To document the challenges in terms of response evaluation to these agentsTimepoint: 1 Years—

Countries

India

Contacts

Public ContactDr Amita Mahajan

Indraprastha Apollo Hospitals

mahajanamita1@gmail.com9810734137

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026